Interesting disclaimer from Novavax, apparently in response to Jefferies' analyst Roger Song's maintaining a $31 price target for this currently priced $14 stock.
An 8-K filed by Novavax yesterday provided the following:
"Item 7.01. Regulation FD Disclosure.
Novavax, Inc. (“Novavax”) is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax’s management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season. Novavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024."
I think if Novavax has successfully integrated Humanigen's patented lenz/vaccine cocktail into their and Sanofi's CIC product, then we, Novavax, and Sanofi will become the covid and CIC market leaders, leaving the mRNA covid vaccines on the shelf, where they belong.